Safety and Efficacy of Oral Cladribine in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the 96 Week Phase IIIb Extension Trial to the CLARITY Study

被引：0
|
作者：
Giovannoni, Gavin [1 ]
Comi, Giancarlo [2 ]
Cook, Stuart [3 ]
Rammohan, Kottil [4 ]
Rieckmann, Peter [5 ]
Soelberg-Sorensen, Per [6 ]
Vermersch, Patrick [7 ]
Hamlett, Anthony [8 ]
Scaramozza, Matthew [9 ]
Lachenal, Nathalie [10 ]
机构：
[1] Barts & London Queen Marys Sch Med & Dent, Blizard Inst, London, England
[2] Inst Expt Neurol, Milan, Italy
[3] Univ Med & Dent New Jersey, Newark, NJ 07103 USA
[4] Ohio State Univ, Miami, FL USA
[5] Dept Neurol, Bamberg, Germany
[6] Danish MS Ctr, Copenhagen, Denmark
[7] Univ Lille, Lille, France
[8] EMD Serono Inc, Rockland, NY USA
[9] EMD Serono Inc, Rockland, MA USA
[10] Merck Serono, Geneva, Switzerland
来源：
NEUROLOGY | 2013年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P07119
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Safety, Tolerability, and Efficacy of Oral Therapies for Relapsing-Remitting Multiple Sclerosis
    Jiwon Oh
    Paul W. O’Connor
    CNS Drugs, 2013, 27 : 591 - 609
  • [42] Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study
    Comi, Giancarlo
    Cook, Stuart
    Rammohan, Kottil
    Sorensen, Per Soelberg
    Vermersch, Patrick
    Adeniji, Abidemi K.
    Dangond, Fernando
    Giovannoni, Gavin
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2018, 11 : 1 - 11
  • [43] Clinical results of a phase III trial of oral myelin in relapsing-remitting multiple sclerosis
    Panitch, H
    Francis, G
    ANNALS OF NEUROLOGY, 1997, 42 (03) : T262 - T262
  • [44] MRI results of a phase III trial of oral myelin in relapsing-remitting multiple sclerosis
    Francis, G
    Evans, A
    Panitch, H
    ANNALS OF NEUROLOGY, 1997, 42 (03) : T289 - T289
  • [45] Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension Study
    Gorrod, Helen Bell
    Latimer, Nicholas R.
    Damian, Doris
    Hettle, Robert
    Harty, Gerard T.
    Wong, Schiffon L.
    VALUE IN HEALTH, 2019, 22 (07) : 772 - 776
  • [46] Safety and tolerability of short-course oral treatment with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study
    Cook, S.
    Vermersch, P.
    Comi, G.
    Giovannoni, G.
    Rammohan, K.
    Rieckmann, P.
    Soelberg-Sorensen, P.
    Chang, P.
    Hamlett, A.
    Musch, B.
    Viglietta, V.
    Greenberg, S.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 285 : S206 - S206
  • [47] Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a phase II, randomised, multicentre trial
    Kappos, L.
    Li, D.
    Calabresi, P.
    O'Connor, P.
    Bar-Or, A.
    Barkhof, F.
    Wells, C.
    Leppert, D.
    Masterman, D.
    Tinbergen, J.
    Hauser, S. L.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 140 - 141
  • [48] Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: Week 144 results of a Phase II, randomised, multicentre trial
    Kappos, L.
    Bar-Or, A.
    Sauter, A.
    Leppert, D.
    Li, D.
    Masterman, D.
    Barkhof, F.
    Tinbergen, J.
    O'Connor, P.
    Calabresi, P. A.
    Hauser, S. L.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (12) : 1875 - 1875
  • [49] Consistent reductions in MRI activity with cladribine tablets therapy for patients with relapsing-remitting multiple sclerosis in the CLARITY study
    Comi, G.
    Cook, S.
    Giovannoni, G.
    Rammohan, K.
    Rieckmann, P.
    Soelberg-Sorensen, P.
    Vermersch, P.
    Hamlett, A.
    Musch, B.
    Fevr, T.
    Viglietta, V.
    Greenberg, S. J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 : 485 - 485
  • [50] Magnetic resonance imaging (MRI) outcomes in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets: results from the CLARITY study, a 96-week, phase III, double-blind, placebo-controlled trial
    Comi, G.
    Cook, S.
    Giovannoni, G.
    Rammohan, K.
    Rieckmann, P.
    Soelberg-Sorensen, P.
    Vermersch, P.
    Chang, P.
    Hamlett, A.
    Musch, B.
    Fevr, T.
    Greenberg, S.
    JOURNAL OF NEUROLOGY, 2009, 256 : S49 - S50
12345